Mon Alopécie - http://mon.alopecie.free.fr: février 2005

Bonjour,

Voici les nouveaux articles parus dans la presse scientifique ces 2 derniers mois.

Pour toute traduction vous pouvez essayer la traduction automatique de Google en cliquant ICI
attention les mots en francais sont traduis en francais et cela devient etrange mais c'et mieux que de ne rien comprendre en anglais.

Jérôme


J Am Acad Dermatol. 2005 Feb;52(2 Pt 2):8-11.: CONGENITAL ALOPECIA AREATA.
Lenane P, Pope E, Krafchik B.

Alopecia areata, the alleged autoimmune process leading to nonscarring hair loss, is not uncommon. It has been classified as an acquired cause of alopecia; however, recently it has been reported in the neonatal period. We report 4 cases of congenital alopecia areata with follow-up from 3 to 5 years. The diagnosis was made clinically in all cases. All patients had prolonged periods of quiescence of hair loss ranging from 6 to 24 months. Treatments used included minoxidil 2% and a range of topical steroids including hydrocortisone 1%, betamethasone valerate 0.05%, fluocinonide 0.05%, and clobetasol propionate 0.05%. The best regrowth observed resulted from the use of clobetasol propionate 0.05%, giving full regrowth in 50% of those treated. Alopecia areata can occur at all ages and, thus, can be classified as both an acquired and a congenital disorder resulting in hair loss.

PMID: 15692503 [PubMed - in process] Source - PubMed

J Am Acad Dermatol. 2005 Feb;52(2 Pt1):287-90.: PLACEBO-CONTROLED ORAL PULSE PREDNISOLONE THERAPY IN ALOPECIA AREATA.
Kar BR, Handa S, Dogra S, Kumar B.

Background Systemic corticosteroids administered as pulse therapy have been found helpful in a wide array of diseases including alopecia areata (AA). None of the studies published so far regarding their use in AA have been randomized or placebo-controlled. Objective We sought to compare the efficacy of weekly oral prednisolone pulse therapy in a placebo-controlled trial for patients with extensive AA. Methods A total of 43 patients were randomly divided into two groups. Patients in group A (23 patients) were treated with oral prednisolone (200 mg once weekly, 5 40-mg tablets) and patients in group B (20 patients) were given placebo tablets on an identical schedule. The total study period was 6 months, consisting of 3 months of active therapy followed by another 3 months of observation. Results Significant hair regrowth was obtained in 8 patients in the prednisolone-treated group. Two of the responders experienced a relapse during the observation period of 3 months. In the placebo group, none of the patients had significant hair regrowth at the end of the study. Conclusion Oral prednisolone pulse therapy is useful in AA. Placebo-controlled studies with varying dosage schedules are required to standardize the dose of prednisolone used in pulse therapy, optimize the therapeutic efficacy, and minimize side effects.

PMID: 15692475 [PubMed - in process] Source - PubMed

BMC Dermatol. 2005 Jan 12;5(1):1.: CONCEPTS OF PATIENTS WITH ALOPECIA AREATA ABOUT THEIR DISEASE.
Firooz A, Firoozabadi MR, Ghazisaidi B, Dowlati Y.

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran. firozali@sina.tums.ac.ir

BACKGROUND: Alopecia areata (AA) is a common and chronic skin disease with an unknown etiology. It may significantly affect the patient quality of life. This study was designed to evaluate the illness perception in patients with AA. METHODS: A questionnaire consisting of 25 questions about causes, timeline, consequences and control of disease were given to 80 patients with AA attending a skin clinic in Tehran, Iran. The impact of age, gender, duration of disease, education, extent of disease and family history of AA were also assessed. RESULTS: Eighty patients (38 male and 42 female) with a mean age of 27.5 years (SD = 9.3) and disease duration of 7.8 years (SD = 7.7) completed the questionnaire. 76.9% of the patients believed that the role of stress was the cause of disease. 17.1 % believed genetic background to be the main cause, this found to be more frequent in patients with positive family history of AA. More than half of patients believed that their illness had major consequences on their lives and 40% of patients believed that their illness would be likely to be permanent rather than temporary, more in patients with longer duration of disease. Only 57.5% of patients considered their treatments to be effective. CONCLUSION: AA may considerably affect various aspects of patients' lives. The patient knowledge about the causes and course of this disease is limited.

PMID: 15644147 [PubMed - in process] Source-PubMed

Eur J Dermatol. 2004 Nov-Dec;14(6):364-70.: ALOPECIA AREATA: AUTOIMMUNE BASIS OF HAIR LOSS.
Alexis AF, Dudda-Subramanya R, Sinha AA.

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.

Alopecia areata (AA) is a heterogeneous disease characterized by nonscarring hair loss on the scalp or any hair-bearing surface. A wide range of clinical presentations can occur -- from a single patch of hair loss to complete loss of hair on the scalp (alopecia totalis) or the entire body (alopecia universalis). Particularly in severe or chronic cases, AA may cause considerable psychological and emotional distress for affected individuals. The estimated lifetime risk of developing AA is 1.7%. While the precise etiology of this common disorder has not been elucidated, a substantial body of evidence suggests that AA is an organ-specific, autoimmune disease, targeted to hair follicles. However, the antigenic target(s), mechanisms, and consequences of autoimmune attack in AA have yet to be determined. Here, we critically explore the evidence supporting the hypothesis that AA is an autoimmune disease and propose specific pathways by which self-directed immune responses are generated.

PMID: 15564197 [PubMed - in process] Source - PubMed

Rev Med Brux. 2004 Sep;25(4):A282-5.: ALOPECIA AREATA AND TREATMENT
[Article in French]

Stene JJ.

Service de Dermatologie, CHU Saint-Pierrre, ULB, Bruxelles.

Alopecia areata is a non scarring inflammatory hair disease, frequently recurrent. It commonly presents as round patches of hair loss which can be the first manifestation of a more severe alopecia: totalis or universalis. A CD4 lymphocytic infiltrate surrounds the hair follicle and is presumed to play a role in the hair fall. There are many treatments available which may help stimulate regrowth. The efficacy, risks, and benefits of each treatment have to be considered when choosing a treatment plan.

PMID: 15516057 [PubMed - in process]

Bonjour,

voici les statistiques du site Mon alopécie pour le mois de Janvier 2005 :
977 visites et 2586 pages vues

voici les mots clés utilisés dans un moteur de recherche pour aboutir sur ce site

n°	Requêtes	%	Nombre	Période - 1
1	alopecie	67.29 %	72	+42
2	mon alopécie	9.35 %	10	+10
3	pelade	3.74 %	4	+3
4	alopecie de stress	1.87 %	2	+2
5	carte alopécie	0.93 %	1	+1
6	alopecie photos	0.93 %	1	+1
7	alopécie pelade	0.93 %	1	+1
8	pelade universalis	0.93 %	1	+1
9	mon.alopecie.free.fr	0.93 %	1	+1
10	la pelade	0.93 %	1	+0
11	mon.alopecie	0.93 %	1	+0
12	"alopécie"	0.93 %	1	+1
13	pelade repousse	0.93 %	1	+1
14	l'alopecia areata	0.93 %	1	+1
15	alopécie vivre avec	0.93 %	1	+1
16	lutter contre "alopecie"	0.93 %	1	+1
17	bien vivre la pelade	0.93 %	1	+1
18	alopecia universalis mon alopecie	0.93 %	1	+1
19	alopecia areata belgique	0.93 %	1	+1
20	maladie "cuire chevelu"	0.93 %	1	+1
21	alopecie ou pelade	0.93 %	1	+1
22	on alopécie	0.93 %	1	+1
23	maladie d'alopécia	0.93 %	1	+1

et la provenance des visiteurs

France	68.85 %	294	+3.5 pt
Belgique	9.60 %	41	-1.5 pt
Etats-unis	7.26 %	31	-3.0 pt
Canada	5.15 %	22	+1.2 pt
Suisse	3.04 %	13	-0.1 pt
Maroc	1.17 %	5	+0.3 pt
Roumanie	0.70 %	3	+0.7 pt
Royaume-uni	0.70 %	3	-0.6 pt
Pays-bas	0.70 %	3	+0.7 pt
Danemark	0.47 %	2	+0.5 pt

N'oubliez pas de vous inscrire et de promouvoir ce site !!

Mon Alopécie - http://mon.alopecie.free.fr

Site principal

jeudi 24 février 2005

Nouvelle Inscription

samedi 19 février 2005

Alrte MSN messenger

vendredi 18 février 2005

Nouvelle inscription

lundi 14 février 2005

Nouvelles inscriptions

samedi 12 février 2005

Nouvelle inscription, Nouvelles Pages Perso

samedi 5 février 2005

Revue Presse Scientifique

vendredi 4 février 2005

Statistiques du site - Mon alopécie-